{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:15Z","timestamp":1787027775272,"version":"build-2736575974"},"reference-count":37,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The aim of this study was to validate a new definition of borderline resectable pancreatic ductal adenocarcinoma (PDAC) provided by the 2017 international consensus on the basis of three dimensions of anatomical (A), biological (B), and conditional (C) factors, using the data of the patients who had been registered for our institutional protocol of chemoradiotherapy followed by surgery (CRTS) for localized patients with PDAC. Methods: Among 307 consecutive patients pathologically diagnosed with localized PDAC who were enrolled in our CRTS protocol from February 2005 to December 2016, we selected 285 patients who could be re-evaluated after CRT. These 285 patients were classified according to international consensus A definitions as follows: R (resectable; n = 62), BR-PV (borderline resectable, superior mesenteric vein (SMV)\/portal vein (PV) involvement alone; n = 27), BR-A (borderline resectable, arterial involvement; n = 50), LA (locally advanced; n = 146). Disease-specific survival (DSS) was analyzed according to A, B (serum CA 19-9 levels and lymph node metastasis diagnosed by computed tomography findings before CRT), and C factors (performance status (PS)) factors. Results: The rates of resection and R0 resection were similar between R (83.9 and 98.0%) and BR-PV (85.2 and 95.5%), but much lower in BR-A (70.0 and 84.8%) and LA (46.6 and 62.5%). DSS evaluated by median survival time (months) showed a similar trend to surgical outcomes: 33.7 in R, 27.3 in BR-PV, 18.9 in BR-A and 19.3 in LA, respectively. DSS in R patients with CA 19-9 levels &gt; 500 U\/mL was significantly poorer than in patients with CA 19-9 levels \u2264 500 U\/mL, but there were no differences in DSS among BR-PV, BR-A, and LA patients according to CA 19-9 levels. Regarding lymph node metastasis, there was no significant difference in DSS according to each resectability group. DSS in R patients with PS \u2265 2 was significantly worse than in patients with PS 0-1. Conclusions: The international consensus on the definition of BR-PDAC based on three dimensions of A, B, and C is useful and practicable because prognosis of PDAC patients is influenced by anatomical factors as well as biological and conditional factors, which in turn may help to decide treatment strategy.<\/jats:p>","DOI":"10.3390\/cancers10030065","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T07:37:25Z","timestamp":1520321845000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer"],"prefix":"10.3390","volume":"10","author":[{"given":"Aoi","family":"Hayasaki","sequence":"first","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Isaji","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kishiwada","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Fujii","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Iizawa","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tanemura","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Murata","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Azumi","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-544X","authenticated-orcid":false,"given":"Shugo","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Usui","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1245\/s10434-009-0670-7","article-title":"Resectable pancreatic cancer: Who really benefits from resection?","volume":"16","author":"Barugola","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/jso.20719","article-title":"The case for routine use of adjuvant therapy in pancreatic cancer","volume":"95","author":"Kennedy","year":"2007","journal-title":"J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2005.06.022","article-title":"Recent updates on the role of chemotherapy in pancreatic cancer","volume":"32","author":"Burris","year":"2005","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pan- creatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11210","DOI":"10.3748\/wjg.v20.i32.11210","article-title":"Selectioncriteria in resectable pancreatic cancer: A biological and morphologicalapproach","volume":"20","author":"Tamburrino","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.6004\/jnccn.2012.0073","article-title":"Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN Guidelines","volume":"10","author":"Tempero","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design","volume":"20","author":"Katz","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","unstructured":"Japan Pancreas Society (2016). Classification of Pancreatic Cancer, Kanehara & Co., Ltd.. [4th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: The importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J. Am. Coll. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPA.0b013e3182236442","article-title":"Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4","volume":"41","author":"Murata","year":"2012","journal-title":"Pancreas"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00534-011-0440-3","article-title":"Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy","volume":"19","author":"Murata","year":"2012","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MPA.0000000000000059","article-title":"Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: Significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression","volume":"43","author":"Kobayashi","year":"2014","journal-title":"Pancreas"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MPA.0000000000000597","article-title":"Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy","volume":"45","author":"Yamada","year":"2016","journal-title":"Pancreas"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Katz, M.H.G., and Ahmad, S.A. (2016). Surgery for borderline pancreatic cancer: The Japanese experience. Multimodal Management of Borderline Resectable Pancreatic Cancer, Springer International Publishing.","DOI":"10.1007\/978-3-319-22780-1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-94-017-7215-0_15","article-title":"CA 19-9: Biochemical and clinical aspects","volume":"867","author":"Botton","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_19","unstructured":"UICC (2017). TNM Classification of Malignant Tumours, John Wiley & Sons, Ltd.. [Eighth ed.]."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s11605-014-2495-3","article-title":"Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma","volume":"18","author":"Mizuno","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1067\/msy.2003.146","article-title":"Radical antegrade modular pancreato-splenectomy","volume":"133","author":"Strasberg","year":"2003","journal-title":"Surgery"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.sla.0000258608.52615.5a","article-title":"Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: Long-term results","volume":"246","author":"Hirano","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: Five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.surg.2005.05.001","article-title":"Postoperative pancreatic fistula: An international study group (ISGPF) definition","volume":"138","author":"Bassi","year":"2005","journal-title":"Surgery"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archsurg.1991.01410310095014","article-title":"Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy","volume":"126","author":"Ishikawa","year":"1991","journal-title":"Arch. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1245\/ASO.2006.02.003","article-title":"Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy","volume":"13","author":"Cheng","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11605-013-2374-3","article-title":"Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer","volume":"18","author":"Balachandran","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.surg.2017.04.023","article-title":"Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society","volume":"162","author":"Yamada","year":"2017","journal-title":"Surgery"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00534-013-0595-1","article-title":"Clinical features and treatment outcome of borderline resectable pancreatic head\/body cancer: A multi-institutional survey by the Japanese Society of Pancreatic Surgery","volume":"20","author":"Kato","year":"2013","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","article-title":"CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy","volume":"20","author":"Hartwig","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MPA.0000000000000315","article-title":"SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer","volume":"44","author":"Yamada","year":"2015","journal-title":"Pancreas"},{"key":"ref_33","unstructured":"Hayasaki, A., Murata, Y., Usui, M., Hibi, T., Ito, T., Iizawa, Y., Kato, H., Tanemura, A., Azumi, Y., and Kuriyama, N. Clinical significance of histological effect and intratumor stromal expression of Tenascin-C in the resected specimens after chemoradiotherapy for initially locally advanced unresectable pancreatic ductal adenocarcinoma. Pancreas, in press."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10147-012-0474-9","article-title":"Performance status of patients is the major prognostic factor at all stages of pancreatic cancer","volume":"18","author":"Tas","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11605-013-2371-6","article-title":"Morbidity and mortality afterpancreaticoduodenectomy in patients with borderline resectable type C clinical classification","volume":"18","author":"Tzeng","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pan.2015.04.004","article-title":"Host systemic inflammatory response influences outcome in pancreatic cancer","volume":"15","author":"Imrie","year":"2015","journal-title":"Pancreatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/01635581.2016.1250921","article-title":"The significance of the prognostic nutritional index for all stages of pancreatic cancer","volume":"69","author":"Lee","year":"2017","journal-title":"Nutr. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/3\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:57:33Z","timestamp":1760194653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/3\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["cancers10030065"],"URL":"https:\/\/doi.org\/10.3390\/cancers10030065","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]}}}